An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alnylam Pharmaceuticals, Inc. (ALNY) will announce its first quarter 2024 financial results on May 2, 2024. The company will discuss its performance and future outlook via a conference call at 8:30 am ET. Participants can register online to access the call and a replay will be available afterward. A live webcast will be accessible on the Investors section of the company's website.
Alnylam Pharmaceuticals, Inc. (ALNY) annuncerà i risultati finanziari del primo trimestre del 2024 il 2 maggio 2024. La società discuterà delle proprie prestazioni e delle prospettive future attraverso una teleconferenza alle 8:30 del mattino, ora dell'Est. I partecipanti possono registrarsi online per accedere alla chiamata e una registrazione sarà disponibile successivamente. Una trasmissione web in diretta sarà accessibile nella sezione Investitori del sito web dell'azienda.
Alnylam Pharmaceuticals, Inc. (ALNY) anunciará sus resultados financieros del primer trimestre de 2024 el 2 de mayo de 2024. La compañía discutirá su rendimiento y perspectivas futuras mediante una llamada de conferencia a las 8:30 a.m. ET. Los participantes pueden registrarse en línea para acceder a la llamada y estará disponible una repetición posteriormente. Una transmisión en vivo estará accesible en la sección de Inversores del sitio web de la empresa.
알닐람 파마슈티컬스, 인크. (ALNY)는 2024년 5월 2일에 2024년 첫 분기 재무 결과를 발표할 예정입니다. 회사는 동부 표준시 오전 8시 30분에 컨퍼런스 콜을 통해 성과와 미래 전망에 대해 논의할 것입니다. 참가자는 온라인으로 등록하여 콜에 접속할 수 있으며, 이후에는 재생이 가능할 것입니다. 생중계 웹캐스트는 회사 웹사이트의 투자자 섹션에서 접근할 수 있습니다.
Alnylam Pharmaceuticals, Inc. (ALNY) annoncera ses résultats financiers pour le premier trimestre de 2024 le 2 mai 2024. La société discutera de ses performances et perspectives d'avenir lors d'une conférence téléphonique à 8h30 ET. Les participants peuvent s'inscrire en ligne pour accéder à l'appel et un replay sera disponible par la suite. Une webdiffusion en direct sera accessible dans la section Investisseurs du site web de l'entreprise.
Alnylam Pharmaceuticals, Inc. (ALNY) wird am 2. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen wird seine Leistung und Zukunftsaussichten in einer Telefonkonferenz um 8:30 Uhr ET besprechen. Teilnehmer können sich online registrieren, um Zugang zur Konferenz zu erhalten und im Anschluss wird eine Aufzeichnung verfügbar sein. Ein Live-Webcast wird im Investorenbereich der Unternehmenswebsite zugänglich sein.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open.
Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future via conference call on Thursday, May 2, 2024 at 8:30 am ET. To access the call, please register online at https://register.vevent.com/register/BI0abdd195e81a43d9ac0c44fe9d789f86. Participants are requested to register a day in advance or at a minimum 15 minutes before the start of the call. A replay of the call will be available two hours after the call and archived on the same web page for six months.
A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or on Instagram.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
